Online citations, reference lists, and bibliographies.
← Back to Search

The Role Of PET In The Surgical Management Of Malignant Pleural Mesothelioma.

R. Flores
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Current imaging modalities fail to define precisely the extent of disease in MPM and are inaccurate in selecting patients for treatment. Previous studies have shown that CT and MRI provide anatomical information that is often imprecise in the preoperative staging of MPM. Consequently, about 25% of patients are found to have unresectable tumor at the time of exploratory thoracotomy. PET is now widely recognized as an important staging modality in many cancers, and PET SUV is reported as a prognostic indicator in several malignancies. However, only a few previous studies have investigated the utility of FDG PET scan in MPM. From 1998 to 2003, 65 patients with MPM underwent PET scans. Median PET SUV in the primary tumor was 6.6 (range, 2-23). The median follow-up for all surviving patients was 16 months. Median survivals were 14 and 24 months for the high and low SUV groups, respectively. In a multivariable analysis, high SUV tumors were associated with a 3.3 times greater risk of death than low SUV tumors (p = 0.03). Mixed histology carried a 3.2 times greater risk of death than epithelial histology (p = 0.03). SUV of >4 and mixed histology are poor risk factors in malignant pleural mesothelioma. These findings suggest that FDG-PET can be used to stratify patients for treatment and clinical trials.
This paper references



This paper is referenced by
10.2217/bmm.11.18
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
10.1201/B13694-51
Asbestos: Profound Evidence for Disease Associations
Yoshiaki Ōmura (2012)
10.1016/S0761-8417(07)78422-5
Le mésothéliome pleural malin : incertitudes et espoirs face à une épidémie annoncée
J. Margery (2007)
10.1097/MNM.0000000000000402
The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma
O. Ozmen (2016)
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
V. Ambrosini (2005)
10.1510/icvts.2010.255901
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
10.1002/9780470025079.CHAP49.PUB2
Pleura and Peritoneum
M. Sheaff (2007)
10.1111/j.1759-7714.2010.00001.x
Management of malignant pleural mesothelioma
P. Hürmüz (2010)
10.1016/j.lungcan.2015.08.012
Response evaluation in mesothelioma: Beyond RECIST.
Lin Cheng (2015)
10.1007/s00259-018-4056-6
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients
E. Incerti (2018)
10.1007/978-88-470-1938-6_17
Diseases of the Chest Wall, Pleura, and Diaphragm
J. Verschakelen (2007)
10.1007/s00066-011-2234-6
PET-guided dose escalation tomotherapy in malignant pleural mesothelioma
Andrei Fodor (2011)
10.1097/RLU.0b013e31828da61d
Multiple primary hepatic malignant mesotheliomas mimicking cystadenocarcinomas on enhanced CT and FDG PET/CT.
A. Dong (2014)
10.1510/icvts.2010.255893
What is the best way to diagnose and stage malignant pleural mesothelioma?
I. Zahid (2011)
Malignes Pleuramesotheliom und maligne Pleuraergüsse
R. Loddenkemper (2008)
10.1517/14728214.12.1.127
Emerging drugs for mesothelioma
G. Scagliotti (2007)
10.1016/B978-0-443-06694-8.50081-6
Tumors of the Pleura and Mediastinum
M. Sovak (2008)
10.1259/bjr.20170814
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
H. S. Elliott (2018)
10.1016/B978-1-4160-3624-1.00001-9
1 – Imaging Tumors of the Lung and Pleura
E. Marom (2010)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.1016/j.soc.2020.06.002
Updates in Staging and Management of Malignant Pleural Mesothelioma.
A. Wolf (2020)
The Efficiency and Toxicity of Hemithoracic Radiotherapy After Extra Pleural Pneumonectomy in Malign Pleural Mesothelioma
P. Hurmuz (2010)
10.1097/JTO.0b013e31816fca1b
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
10.1007/s00259-013-2561-1
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma
A. Klabatsa (2013)
10.1016/J.HOC.2005.09.009
Prognostic factors for mesothelioma.
J. Steele (2005)
10.1967/s002449910162
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
V. A. Marín-Oyaga (2015)
10.1007/S00761-014-2886-9
Pleuramesotheliome: Multimodales Management als klinische Herausforderung
Rudolf A. Hatz (2015)
Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Sabrina Di Bartolomeo (2016)
Malignant pleural mesothelioma: utility of 18 F-FDG PET.
M. G. Spitilli (2007)
10.1016/B978-1-4377-2232-1.00008-5
Chapter 8 – Pleural Tumors
M. Truong (2012)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar